市場調查報告書
商品編碼
1416322
放射配體治療市場報告:2030 年趨勢、預測與競爭分析Radioligand Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
放射配體治療的趨勢和預測
預計到 2030 年,全球放射配體治療市場將達到約 138 億美元,2024 年至 2030 年的複合年成長率為 5.0%。該市場的主要促進因素是癌症發病率的上升和對有效治療的高需求。全球放射配體治療市場的未來看起來充滿希望,醫院、診所和診斷中心市場充滿機會。
放射配體治療市場洞察
Lucintel 預測,由於癌症診斷的高需求,氟 18 在整個預測期內仍將是最大的細分市場。
由於久坐生活方式的普及和全球癌症病例的不斷增加,醫院將繼續成為該市場的最大細分市場。
由於專門的癌症醫院和研究中心的存在以及全部區域的癌症發病率增加,北美在預測期內可能仍然是最大的地區。
Q1.市場規模為:
A1. 到 2030 年,全球放射配體治療市場預計將達到 138 億美元。
Q2.市場成長預測是多少:
A2. 2024年至2030年,全球放射配體治療市場預計將以5.0%的複合年成長率成長。
Q3.影響市場成長的主要促進因素是:
A3. 該市場的主要促進因素是癌症發生率的上升和對有效治療的高需求。
Q4.市場的主要細分市場是:
A4. 放射配體治療市場的未來前景廣闊,醫院、診所和診斷中心市場充滿機會。
Q5.市場的主要企業是:
A5. 主要的放射配體治療公司是:
Q6.未來最大的細分市場是什麼?
A6.Lucintel 預計,由於癌症診斷的高需求,氟 18 在整個預測期內仍將是其最大的細分市場。
Q7. 未來五年預計哪些地區的市場成長最大?
A7. 由於專門的癌症醫院和研究中心的存在以及全部區域癌症發病率的增加,預計北美在預測期內仍將是最大的地區。
Q8. 可以客製化報告嗎?
A8. 是的,Lucintel 提供 10% 的客製化服務,無需額外付費。
Radioligand Therapy Trends and Forecast
The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and high demand for effective treatment.
A more than 150-page report is developed to help in your business decisions.
Radioligand Therapy by Segment
The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.
Radioligand Therapy Market by Isotope [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by Targeted Receptor [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:
List of Radioligand Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-
Radioligand Therapy Market Insights
Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.
Within this market, hospitals will remain the largest segment due to increasing prevalence of a sedentary way of living and growing cases of cancer across the globe.
North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.
Features of the Global Radioligand Therapy Market
Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).
Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the radioligand therapy market size?
Answer: The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030.
Q2. What is the growth forecast for radioligand therapy market?
Answer: The global radioligand therapy market is expected to grow with a CAGR of 5.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the radioligand therapy market?
Answer: The major drivers for this market are rising cancer rates and high demand for effective treatment.
Q4. What are the major segments for radioligand therapy market?
Answer: The future of the radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets.
Q5. Who are the key radioligand therapy market companies?
Answer: Some of the key radioligand therapy companies are as follows:
Q6. Which radioligand therapy market segment will be the largest in future?
Answer: Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.
Q7. In radioligand therapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.